GSK has won its latest trial over whether its former best-selling ... known as NDMA that had been found in GSK’s heartburn drug Zantac; also known as ranitidine. The decision is the latest ...

Aug 5 (Reuters) - GSK (GSK.L), opens new tab won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for ...

GSK and Boehringer Ingelheim are the only defendants in the trial, after other ... and does not contain ranitidine. The companies notched a significant win in 2022 when a judge dismissed about ...

A month before it was set to take the stand in the highly anticipated first Zantac-related trial, GSK scratched ... Last month, GSK saw a win in a key class-action suit in Canada after the British ...

As GSK's July court date nears for a key Zantac trial in California, the company can wipe its hands of at least one Canadian class-action suit. The company said in a Friday statement that it “we ...

Zamboni is expected to say the ‘Tanner study — which was not submitted to the FDA until 2019 — provides evidence that GSK knew about Zantac’s potential health impacts, but failed to make ...

GSK Plc convinced an Illinois jury that the former heartburn drug Zantac was not liable for a woman’s colorectal cancer in a second trial win for the British drugmaker. It comes just over two ...

GSK has won its latest trial over whether its former best-selling drug caused ... from a contaminant known as NDMA that had been found in GSK’s heartburn drug Zantac; also known as ranitidine. The ...